AstraZeneca has announced the suspension of a 200 million pound investment in the research center in Cambridge, affecting 1,000 jobs.
Raluca Ioana Draghici
Economy
www.shutterstock.com
Always see our news on Google
AstraZeneca has decided to halt its £200 million investment plan at its research center in Cambridge, a project that would have created approximately 1,000 jobs. This is the company's second major withdrawal from the UK in 2024, after it abandoned a £450 million investment in vaccine manufacturing in January. The decisions of pharmaceutical companies, including Merck & Co., are putting pressure on the British government in the context of maintaining attractiveness for investments in the pharmaceutical sector.
Sources
AstraZeneca suspendă o investiţie de 270 de milioane de dolari în Marea Britanie
Britain’s biggest company AstraZeneca pauses £200m investment into Cambridge site
AstraZeneca pauses £200m Cambridge investment
Britain’s biggest company AstraZeneca pauses £200m investment into Cambridge site
Latest News
22:06
Air traffic controllers in Norway have gone on strike, causing the cancellation of dozens of flights. The Ministry of Foreign Affairs warns Romanian citizens to check their flights.
21:54
Romania has sent the rescEU Black Hawk helicopter to support Serbia in combating the wildfires that have affected 3,500 hectares.
21:39
Unprecedented lows on the Jiu River. Hydrologists announce a historic minimum at the hydrometric stations in Filiași and Răcari.
21:22
A fragment of a drone was found near the southern dam of the Midia Port and recovered by military divers. The Ministry of National Defense confirmed that it does not present explosive charges.
21:02
The Kremlin dismissed speculation about a meeting between President Vladimir Putin and rapper Kanye West
See more news
NEWS ON THE SAME TOPICS
International
AstraZeneca, negotiations with Bristol Myers Squibb for a possible merger that could create a 400 billion dollar group
International
AstraZeneca announced the failure of a drug for a rare heart condition, causing a 9% drop in the company's shares.
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
